Pfizer Inc (PFE)
Pretax margin
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Earnings before tax but after interest (EBT) | US$ in thousands | 8,023,000 | 1,058,000 | 34,729,000 | 24,311,000 | 7,497,000 |
| Revenue | US$ in thousands | 63,627,000 | 58,496,000 | 100,330,000 | 81,288,000 | 41,908,000 |
| Pretax margin | 12.61% | 1.81% | 34.61% | 29.91% | 17.89% |
December 31, 2024 calculation
Pretax margin = EBT ÷ Revenue
= $8,023,000K ÷ $63,627,000K
= 12.61%
Pfizer Inc's pretax margin has shown fluctuations over the years. The pretax margin increased from 17.89% in December 2020 to 29.91% by December 2021, indicating improved profitability before taxes. In December 2022, the pretax margin further increased to 34.61%, reflecting strong financial performance. However, there was a notable decline in December 2023, with the pretax margin dropping to 1.81%, potentially indicating challenges or expenses impacting profitability. By December 2024, the pretax margin showed a partial recovery, increasing to 12.61%. Overall, the trend highlights both the strengths and potential challenges in Pfizer Inc's financial performance over the analyzed period.
Peer comparison
Dec 31, 2024